.png)

"As a prostate cancer survivor,
it is a privilege to be able to contribute to a study that has the potential to deliver new methods of testing for prostate cancer that are more reliable, more accurate and less invasive than the current prostate-specific antigen (PSA) test and biopsies. Not all men with prostate cancer are as fortunate as me; I had symptoms that indicated a problem, even though my PSA result was 'normal', but many men have no symptoms at all. We need a test that clinicians and patients can trust."
ABOUT US

The ReIMAGINE Consortium is a pioneering prostate cancer research programme comprising three complementary studies: ReIMAGINE[Risk], ReIMAGINE[Screening] and ReIMAGINE[Life].
Together, these studies aim to improve how prostate cancer is identified, detected, stratified and managed, helping to deliver more personalised care for men across the disease pathway.
By combining advanced imaging, biological samples, clinical data and patient involvement, the Consortium is generating evidence to support earlier detection, more accurate risk assessment and improved long-term outcomes.


